PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY

被引：0
|
作者：
Kaplan, Jess
Bousvaros, Athos
Turner, Dan
Dubinsky, Marla C.
Komocsar, Wendy
Larkin, Amy E.
Johns, Jordan
Zhang, Xin
Little, Cheryl A.
Crandall, Wallace
Arora, Vipin
Hyams, Jeffrey S.
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
781
引用
收藏
页码：S169 / S169
页数：1
相关论文
共 50 条
  • [31] REDUCTION IN INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
    Sandborn, William J.
    Sands, Bruce E.
    Kobayashi, Taku
    Tuttle, Jay
    Schmitz, Jochen
    Durante, Michael
    Higgs, Richard E.
    Canavan, James
    Siegel, Robert
    Ferrante, Marc
    GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1095
  • [32] Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Keohane, A.
    Zhu, B.
    Ritter, T.
    Regueiro, M.
    Hudesman, D.
    Chen, Y. F.
    Owen, C.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1975 - I1976
  • [33] EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
    D'Haens, Geert
    Higgins, Peter D.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard
    Redondo, Isabel
    Escobar, Rodrigo
    Morris, Nathan
    Kobayashi, Taku
    GASTROENTEROLOGY, 2023, 164 (06) : S1086 - S1086
  • [34] Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
    D'Haens, G.
    Higgins, P. D. R.
    Peyrin-Biroulet, L.
    Sands, B. E.
    Lee, S.
    Moses, R. E.
    Redondo, I.
    Escobar, R.
    Morris, N.
    Kobayashi, T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 682 - 682
  • [35] Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
    Friedrich, S.
    Chua, L.
    Zhang, X. C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 646 - 646
  • [36] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM RANDOMISED PHASE 2 AND PHASE 3 INDUCTION AND MAINTENANCE TRIALS
    Friedrich, Stuart
    Chua, Laiyi
    Zhang, Xin
    GASTROENTEROLOGY, 2023, 164 (06) : S1217 - S1218
  • [37] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
    Louis, E.
    Panaccione, R.
    Parkes, G.
    Peyrin-Biroulet, L.
    Ferrante, M.
    Hisamatsu, T.
    Siegmund, B.
    Kalabic, J.
    Levine, P.
    Neimark, E.
    Wallace, K.
    Chen, S.
    Cheng, L.
    Duan, W. R.
    Armuzzi, A.
    Biederman, L.
    Loftus, E.
    Melmed, G.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12
  • [38] Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial
    Danese, Silvio
    Dignass, Axel
    Matsuoka, Katsuyoshi
    Ferrante, Marc
    Long, Millie
    Redondo, Isabel
    Gibble, Theresa Hunter
    Moses, Richard
    Morris, Nathan
    Li, Xingyuan
    Milch, Catherine
    Abreu, Maria T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S535 - S535
  • [39] EFFICACY AND SAFETY OF COMBINATION INDUCTION THERAPY WITH GUSELKUMAB AND GOLIMUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS THROUGH WEEK 12 OF THE PHASE 2A VEGA STUDY
    Feagan, Brian G.
    Sands, Bruce E.
    Sandborn, William J.
    Shipitofsky, Nicole
    Marko, Melissa G.
    Sheng, Shihong
    Johanns, Jewel
    Germinaro, Matthew
    Vetter, Marion
    Panes, Julian
    GASTROENTEROLOGY, 2022, 162 (07) : S215 - S216
  • [40] Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
    Sandborn, William J.
    Ferrante, Marc
    Bhandari, Bal R.
    Berliba, Elina
    Feagan, Brian G.
    Hibi, Toshifumi
    Tuttle, Jay L.
    Klekotka, Paul
    Friedrich, Stuart
    Durante, Michael
    Morgan-Cox, MaryAnn
    Laskowski, Janelle
    Schmitz, Jochen
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2020, 158 (03) : 537 - +
12345